BioNTech Drug Nearly Doubles Survival in Hard-to-Treat Lung Cancer

Updated PRESERVE-003 data: gotistobart showed 18.5 vs 10 months median survival vs chemo in previously treated squamous NSCLC. Pivotal stage ongoing.